Form D · Pharmaceuticals
Intezyne Technologies, Inc.
Tampa, FL · CIK 0001580048
Offering snapshot reported Jun 9, 2016 · SEC filing
- Reported sold
- $480K Offering amount: $12M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 25, 2016 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 9, 2016 | Initial | $480,000 | No comparison | 1 | SEC filing |
| Jun 25, 2013 | Initial | $8,844,359 | No comparison | 52 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-264729
Source: Form D, filed Jun 9, 2016. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Micheal Cole | Director |
| Michael Cole | Director |
| Daniel Devers | Executive |
| Michael Fountain | Director |
| John Mc Bride | Director |
| Carolyn Paradise | Executive |
| Hooshmand Sheshbaradaran | Director |
| Kevin Sill | Executive |
| Habib Skaff | Director, Executive |
| James Trotman | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
3720 Spectrum Boulevard, Suite 104
Tampa, FL, 33612
Tampa, FL, 33612